The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
<h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0211005 |
id |
doaj-39f08790eb6242bc97619700802604e9 |
---|---|
record_format |
Article |
spelling |
doaj-39f08790eb6242bc97619700802604e92021-03-04T10:37:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021100510.1371/journal.pone.0211005The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.Maria Consiglia TrottaRosa MaistoFrancesca GuidaSerena BoccellaLivio LuongoCornel BaltaGiovanbattista D'AmicoHildegard HermanAnca HermeneanClaudio BucoloMichele D'Amico<h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA2 receptors exert an anti-inflammatory effect on the retinal damage induced by diabetes when activated by the endogenous ligand β-hydroxybutyrate.<h4>Methodology</h4>Seven-to-10-week-old C57BL6J mice were rendered diabetic by a single intraperitoneal injection of streptozotocin (75 mg/kg of body weight) and monitored intermittently over a 10-week period extending from the initial diabetes assessment. Mice with a fasting blood glucose level higher than 250 mg/dl for 2 consecutive weeks after streptozotocin injection were treated twice a week with intraperitoneal injections of 25-50-100 mg/kg β-hydroxybutyrate.<h4>Results</h4>Interestingly, while the retinal endoplasmic reticulum stress markers (pPERK, pIRE1, ATF-6α) were elevated in diabetic C57BL6J mice, their levels were significantly reduced by the systemic intraperitoneal treatment with 50 mg/kg and 100 mg/kg β-hydroxybutyrate. These mice also exhibited high NLRP3 inflammasome activity and proinflammatory cytokine levels. In fact, the elevated levels of retinal NLRP3 inflammasome activation markers (NLRP3, ASC, caspase-1) and of the relative proinflammatory cytokines (IL-1β, IL-18) were significantly reduced by 50 mg/kg and 100 mg/kg β-hydroxybutyrate treatment. These doses also reduced the high apoptotic cell number exhibited by the diabetic mice in the retinal outer nuclear layer (ONL) and increased the ONL low connexin 43 expression, leading to an improvement in retinal permeability and homeostasis.<h4>Conclusions</h4>These data suggest that the systemic treatment of diabetic C57BL6J mice with BHB activates retinal HCA2 and inhibits local damage.https://doi.org/10.1371/journal.pone.0211005 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria Consiglia Trotta Rosa Maisto Francesca Guida Serena Boccella Livio Luongo Cornel Balta Giovanbattista D'Amico Hildegard Herman Anca Hermenean Claudio Bucolo Michele D'Amico |
spellingShingle |
Maria Consiglia Trotta Rosa Maisto Francesca Guida Serena Boccella Livio Luongo Cornel Balta Giovanbattista D'Amico Hildegard Herman Anca Hermenean Claudio Bucolo Michele D'Amico The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. PLoS ONE |
author_facet |
Maria Consiglia Trotta Rosa Maisto Francesca Guida Serena Boccella Livio Luongo Cornel Balta Giovanbattista D'Amico Hildegard Herman Anca Hermenean Claudio Bucolo Michele D'Amico |
author_sort |
Maria Consiglia Trotta |
title |
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. |
title_short |
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. |
title_full |
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. |
title_fullStr |
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. |
title_full_unstemmed |
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. |
title_sort |
activation of retinal hca2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the nlrp3 inflammasome. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
<h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA2 receptors exert an anti-inflammatory effect on the retinal damage induced by diabetes when activated by the endogenous ligand β-hydroxybutyrate.<h4>Methodology</h4>Seven-to-10-week-old C57BL6J mice were rendered diabetic by a single intraperitoneal injection of streptozotocin (75 mg/kg of body weight) and monitored intermittently over a 10-week period extending from the initial diabetes assessment. Mice with a fasting blood glucose level higher than 250 mg/dl for 2 consecutive weeks after streptozotocin injection were treated twice a week with intraperitoneal injections of 25-50-100 mg/kg β-hydroxybutyrate.<h4>Results</h4>Interestingly, while the retinal endoplasmic reticulum stress markers (pPERK, pIRE1, ATF-6α) were elevated in diabetic C57BL6J mice, their levels were significantly reduced by the systemic intraperitoneal treatment with 50 mg/kg and 100 mg/kg β-hydroxybutyrate. These mice also exhibited high NLRP3 inflammasome activity and proinflammatory cytokine levels. In fact, the elevated levels of retinal NLRP3 inflammasome activation markers (NLRP3, ASC, caspase-1) and of the relative proinflammatory cytokines (IL-1β, IL-18) were significantly reduced by 50 mg/kg and 100 mg/kg β-hydroxybutyrate treatment. These doses also reduced the high apoptotic cell number exhibited by the diabetic mice in the retinal outer nuclear layer (ONL) and increased the ONL low connexin 43 expression, leading to an improvement in retinal permeability and homeostasis.<h4>Conclusions</h4>These data suggest that the systemic treatment of diabetic C57BL6J mice with BHB activates retinal HCA2 and inhibits local damage. |
url |
https://doi.org/10.1371/journal.pone.0211005 |
work_keys_str_mv |
AT mariaconsigliatrotta theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT rosamaisto theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT francescaguida theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT serenaboccella theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT livioluongo theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT cornelbalta theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT giovanbattistadamico theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT hildegardherman theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT ancahermenean theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT claudiobucolo theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT micheledamico theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT mariaconsigliatrotta activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT rosamaisto activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT francescaguida activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT serenaboccella activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT livioluongo activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT cornelbalta activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT giovanbattistadamico activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT hildegardherman activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT ancahermenean activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT claudiobucolo activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome AT micheledamico activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome |
_version_ |
1714805211469447168 |